Pasithea Therapeutics Corp (KTTA)
5.10
-0.16
(-3.04%)
USD |
NASDAQ |
Jun 17, 16:00
5.10
0.00 (0.00%)
After-Hours: 20:00
Pasithea Therapeutics Net Income (Quarterly): -3.861M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -3.861M |
December 31, 2023 | -5.048M |
September 30, 2023 | -3.613M |
June 30, 2023 | -3.763M |
March 31, 2023 | -3.538M |
December 31, 2022 | -5.118M |
September 30, 2022 | -4.586M |
Date | Value |
---|---|
June 30, 2022 | -2.658M |
March 31, 2022 | -1.574M |
December 31, 2021 | 0.6301M |
September 30, 2021 | -1.526M |
June 30, 2021 | -0.7279M |
March 31, 2021 | -0.5496M |
September 30, 2020 | -0.014M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-5.118M
Minimum
Dec 2022
0.6301M
Maximum
Dec 2021
-2.568M
Average
-3.098M
Median
Net Income (Quarterly) Benchmarks
CEL-SCI Corp | -7.245M |
AIM ImmunoTech Inc | -5.817M |
IGC Pharma Inc | -5.589M |
NovaBay Pharmaceuticals Inc | -3.214M |
Protalix BioTherapeutics Inc | -4.595M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 4.041M |
EPS Diluted (Quarterly) | -3.70 |
Enterprise Value | -6.522M |
Earnings Yield | -272.7% |